ReviewInternational journal of hematology2006
AML1/Runx1 as a versatile regulator of hematopoiesis: regulation of its function and a role in adult hematopoiesis.
Review in International journal of hematology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Expressional changes of genes and miRNA in common megakaryocyte-erythroid progenitors from lower-risk myelodysplastic syndrome.International journal of hematology · 2014Trial
- Leukemic fusion genes repress viral gene expression and expel adenovirus from persistently infected human B lymphocytes but evidence of the virus lingers behind.bioRxiv : the preprint server for biology · 2025Article
- CEBPA double mutations associated with ABO antigen weakness in hematologic diseases.Blood advances · 2024Article
- Review
- Intracranial Aneurysms Induced byFrontiers in neurology · 2022Article
- Expression and Prognosis Analyses of Runt-Related Transcription Factor Family in Human Leukemia.Molecular therapy oncolytics · 2019Article
- RUNX1 promote invasiveness in pancreatic ductal adenocarcinoma through regulating miR-93.Oncotarget · 2017Article
- Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.Cancer research · 2017Article
- Review
- Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner.Experimental hematology · 2015Article
- Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells.The Journal of clinical investigation · 2013Article
- Novel function of the unique N-terminal region of RUNX1c in B cell growth regulation.Nucleic acids research · 2013Article
- Regulation of postnatal forebrain amoeboid microglial cell proliferation and development by the transcription factor Runx1.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2012Article
- Molecular mechanisms of leukemia-associated protein degradation.Frontiers of medicine in China · 2010Review
- The human SWI/SNF complex associates with RUNX1 to control transcription of hematopoietic target genes.Journal of cellular physiology · 2010Article
- Article
- Identification and analysis of the human CD160 promoter: implication of a potential AML-1 binding site in promoter activation.Genes and immunity · 2009Article
- Article
- Additional acquisition of t(1;21)(p32;q22) in a patient relapsing with acute myelogenous leukemia with NUP98-HOXA9.International journal of hematology · 2008Article
- Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes.BMC cancer · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AML1/Runx1, originally identified as a gene located at the breakpoint of the t(8;21) translocation, encodes a transcription factor that is widely expressed in multiple hematopoietic lineages and that regulates the expression of a variety of hematopoietic genes. Numerous studies have shown that AML1 is a critical regulator of hematopoietic development. In addition, AML1 is a frequent target for chromosomal translocation in human leukemia. The activity of AML1 can be modulated by various types of posttranslational modification, including phosphorylation and acetylation. Phosphorylation by extracellular signal-regulated kinase (ERK) is one of the mechanisms that dictate whether AML1 acts as either a transcriptional repressor or an activator of gene expression. Recently, a physiological role for AML1 in adult hematopoiesis was revealed by conditional gene targeting in mice. Remarkably, adult hematopoietic progenitors are maintained even in the absence of AML1, in stark contrast to the total disruption of definitive hematopoiesis during embryogenesis. AML1 is, however, critical for megakaryopoiesis and plays an important role in T-cell and B-cell development in adult mice. Recent analyses engineered to recreate hematopoiesis in vitro revealed that the transcriptional activity of AML1 is closely related with the potential of AML1 to generate hematopoietic cells and support thymocyte development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.